Group 1 - The innovative drug concept index rose by 0.72%, ranking 9th among concept sectors, with 108 stocks increasing in value [1][2] - Notable gainers included Guangshantang and Rejing Bio, both reaching a 20% limit up, while other significant increases were seen in Jingxin Pharmaceutical, Haizheng Pharmaceutical, and Saily Medical, with respective rises of 10.02%, 10.02%, and 18.79% [1][2] - The sector experienced a net outflow of 296 million yuan in principal funds, with 93 stocks receiving net inflows, and five stocks exceeding 100 million yuan in net inflows, led by Zhongyuan Qihua with 183 million yuan [2][3] Group 2 - The top stocks by net inflow ratio included Saily Medical, Aosaikang, and Zhongyuan Qihua, with net inflow rates of 30.63%, 29.89%, and 20.01% respectively [3] - The innovative drug sector's top performers in terms of net inflow included Zhongyuan Qihua, Guangshantang, and Aosaikang, with net inflows of 182.94 million yuan, 156.95 million yuan, and 137.87 million yuan respectively [3][4] - The overall trading activity in the innovative drug sector showed a mix of significant gains and losses, with some stocks like Anlikang and Zhenbaodao experiencing declines of 7.81% and 3.95% respectively [1][2][3]

Group 1 - The China Securities Innovation Drug Industry Index (931152) increased by 0.55%, with notable stock performances including Zhenhua Cell (688520) up 16.46%, Rongchang Bio (688331) up 10.65%, and Aosaikang (002755) up 10.00% [1] - The Innovation Drug 50 ETF (159835) has shown a cumulative increase of 33.49% over the past year, indicating significant growth in its market share [1] - The National Healthcare Security Administration and the National Health Commission released measures to support the high-quality development of innovative drugs, marking a pivotal step in the integration of commercial health insurance into the multi-tiered medical security system [1] Group 2 - Multiple policy releases are seen as significant for the development of innovative drugs, with the introduction of a commercial health insurance innovative drug directory expected to expand market opportunities and encourage pharmaceutical companies to enhance R&D efforts [2] - The domestic innovative drug industry is anticipated to reach a turning point by 2025, shifting from capital-driven growth to profit-driven growth, presenting dual opportunities for performance and valuation recovery [2] - The Innovation Drug 50 ETF closely tracks the China Securities Innovation Drug Industry Index, which selects up to 50 representative listed companies involved in innovative drug R&D to reflect the overall performance of the innovative drug sector [2]

证券代码：002755 证券简称：奥赛康 公告编号：2025-038 北京奥赛康药业股份有限公司 关于利厄替尼片（奥壹新®）III 期临床研究结果在 自 2021 年 6 月 30 日至 2022 年 9 月 22 日，共有 595 例患者参与筛选，其中 337 例患者随机分配至利厄替尼组（N=168）或吉非替尼组（N=169），所有 337 例患者均纳入全分析集。 《柳叶刀·呼吸病学》发布的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 北京奥赛康药业股份有限公司（以下简称"公司"）一类创新药利厄替尼片 （奥壹新®）近日在国际顶级医学期刊《柳叶刀·呼吸病学》（IF:32.8）发布该产品 的 III 期临床研究结果。利厄替尼片是第三代表皮生长因子受体（EGFR）酪氨酸 激酶抑制剂（TKI），用于具有 EGFR 突变的局部晚期或转移性非小细胞肺癌 （NSCLC）成人患者的一线、二线治疗。相关情况如下： 一、临床研究相关情况 （一）研究背景 此次发表的临床研究由中国医学科学院肿瘤医院石远凯教授担任主要研究 者，共有 56 家中国临床中心参与，是一项多中心、随 ...

Group 1: Fudan Zhangjiang - Shareholders Yang Zongmeng and Wang Haibo plan to reduce their holdings by a total of up to 1.41% of the company's shares [1] - Yang Zongmeng intends to sell up to 10.36 million shares, representing 1.00% of the total share capital [1] - Wang Haibo plans to sell up to 4.27 million shares, representing 0.41% of the total share capital [1] Group 2: Aisen Co., Ltd. - Shareholders including Ailong Venture Capital and executives plan to reduce their holdings by a total of up to 3.86% of the company's shares [1] - Ailong Venture Capital intends to sell up to 2.644 million shares, representing 3.00% of the total share capital [1] - Other executives plan to sell smaller amounts, with individual reductions ranging from 0.17% to 0.45% of the total share capital [1] Group 3: Youyou Food - Actual controller Zhao Ying plans to reduce his holdings by up to 3% of the company's shares [3] - The planned reduction amounts to up to 12.83 million shares [3] Group 4: Chenfeng Technology - The company plans to sell idle assets, including 6 vehicles and 53 pieces of machinery, for a total estimated sale price of 8.1461 million yuan [5] - Expected disposal gains from the sale are approximately 3.6238 million yuan [5] Group 5: *ST Hengtai - The company will cancel its delisting risk warning and other risk warnings, with the stock name changing from "*ST Hengtai" to "Henglitai" [6] - The stock will be suspended for one day and the price fluctuation limit will change to 10% [6] Group 6: Xinyunda - Shareholder Wuku International Trust plans to reduce its holdings by up to 3% of the company's shares [9] - The planned reduction amounts to up to 5.9823 million shares [9] Group 7: Shaoyang Hydraulic - The company is planning a major asset restructuring, which involves issuing shares and cash to acquire part or all of Chongqing Xincheng Hangrui Technology Co., Ltd. [10] - The stock will be suspended for up to 10 trading days [10] Group 8: Xingwang Yuda - The company announced that part of its bank account funds, totaling 25.9335 million yuan, have been frozen [11] - The frozen amount represents 1.42% of the company's most recent audited net assets [11] Group 9: Tianrong Tianyu - Shareholder Yan Xuewei plans to reduce his holdings by up to 3% of the company's shares [12] - The planned reduction amounts to up to 4.2089 million shares [12] Group 10: Qiming Star - The chairman Wei Bing has resigned due to work adjustments at China Mobile Communications Group [13] Group 11: Aosaikang - The company's subsidiary has received a drug registration certificate for Methotrexate injection, which is considered equivalent to passing consistency evaluation [15][16] Group 12: Xinhau Optoelectronics - The company plans to transfer 100% equity of its wholly-owned subsidiary, Xinguang Energy Technology (Anhui) Co., Ltd. [17] Group 13: ST Baili - The company's controlling shareholder has been applied for bankruptcy liquidation due to inability to repay debts [19]

证券代码：002755 证券简称：奥赛康 公告编号：2025-037 北京奥赛康药业股份有限公司 关于子公司甲氨蝶呤注射液 获得药品注册证书的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 二、药品相关情况 甲氨蝶呤是一种二氢叶酸还原酶抑制剂类药物，可干扰 DNA 合成、修复和 细胞复制，具有广谱抗肿瘤活性，可单独使用治疗乳腺癌、妊娠性绒毛膜癌等， 或与其它化疗药物联合使用治疗成骨肉瘤、急性白血病等，大剂量单独应用或与 其它化疗药物联合应用治疗成骨肉瘤、急性白血病、支气管肺癌或头颈部表皮癌， 以及用于银屑病化疗。 甲氨蝶呤注射液的原料药由子公司南京海润医药有限公司生产，该原料药已 于 2025 年 5 月获得了上市申请批准通知书。 甲氨蝶呤注射液受到国内外众多指南及专家共识的推荐。PDB数据库显示， 甲氨蝶呤注射液在样本医院近五年的年均销售额约 1.4 亿元，销售市场前景广阔。 三、对公司的影响 北京奥赛康药业股份有限公司（以下简称"公司"）的全资子公司江苏奥赛 康药业有限公司（以下简称"子公司"）于近日收到国家药品监督管理局（以下 简称"药监局"）核准 ...

Core Viewpoint - The company has received the drug registration certificate for Methotrexate Injection from the National Medical Products Administration, which is expected to enhance its competitiveness in the oncology market [1] Group 1: Drug Approval and Market Potential - The company's wholly-owned subsidiary, Jiangsu Aosaikang Pharmaceutical Co., Ltd., has recently obtained the drug registration certificate for Methotrexate Injection [1] - The active pharmaceutical ingredient for Methotrexate Injection received a marketing application approval notice in May 2025 [1] - Methotrexate Injection can be used alone to treat breast cancer and gestational trophoblastic neoplasia, or in combination with other chemotherapy drugs for osteosarcoma and acute leukemia [1] Group 2: Sales Performance and Future Impact - According to the PDB database, the average annual sales of Methotrexate Injection in sample hospitals over the past five years is approximately 140 million yuan [1] - The market outlook for Methotrexate Injection is broad, indicating significant sales potential [1] - The acquisition of the drug registration certificate will enrich the company's oncology product portfolio and positively impact the company's future operations [1]

Summary of Conference Call Notes Industry Overview - The conference focuses on the innovative pharmaceutical sector, particularly the PD-(L)1 Plus treatment landscape, which is becoming a competitive area for overseas pharmaceutical companies [1][2]. Key Insights and Arguments - **Market Performance**: The pharmaceutical sector has shown strong performance recently, with significant volatility in innovative drugs. The core stocks have remained relatively stable during adjustments, driven by short-term trading dynamics [3]. - **Investment Outlook**: There is a strong bullish sentiment towards the innovative drug market, supported by solid underlying logic and clear industry trends. Key innovative drug targets, especially those with BD expectations or PD-1 Plus logic, are expected to perform well even during market corrections [3]. - **Investment Strategy**: Four main investment lines are recommended: Chinese supermarkets, generic drug opportunities, re-evaluation of small-cap pipelines, and large overseas pharmaceuticals. The strategy includes a combination of buying and random rotation for explosive growth [3]. - **Focus Areas**: Attention is drawn to the PD-1 Plus logic, particularly the potential upgrade from PD-1/VEGF to PD-1/IL-2. Upcoming opportunities related to the ADA conference in late June and advancements in medical technology (brain-computer interfaces, rehabilitation robots, AI in healthcare) are highlighted [3]. - **2025 Outlook**: Optimism prevails for the pharmaceutical sector, with expectations of a structural bull market. Focus areas include innovative drugs, new technologies, and industry restructuring [3]. Clinical Data Insights - **Sinda's PD-1/IL-2 (IBI363) Data**: - In non-small cell lung cancer (wild-type), the 1-1.5 mg/kg group showed an ORR of 25.9% and a median OS of 15.3 months, while the 3 mg/kg group had an ORR of 36.7% and a median PFS of 9.3 months, suggesting a potential median OS of 20-25+ months [3]. - In lung adenocarcinoma (wild-type), the low-dose group (0.6/1.5 mg/kg) had an ORR of 13.08% and a median PFS of 2.7 months, while the high-dose group (3 mg/kg) showed an ORR of 24% and a median PFS of 5.6 months, with a potential median OS of 25-30 months [3]. - The data indicates a high OS/PFS ratio, particularly in lung adenocarcinoma, which is rare and suggests a potential to limit metastatic tumors [3][4]. Competitive Landscape - **PD-1 Plus Market**: The PD-(L)1 market is substantial, estimated at around $40 billion, and is undergoing innovation. Major multinational corporations are actively investing in PD-1 Plus, contributing to rising upfront payments in business development [6]. - **Key Companies to Watch**: Notable companies in the PD-1 Plus space include Sinda, Hengrui, BeiGene, Kangfang Biotech, Rongchang Biotech, Aosaikang, and Zhimeng Junshi [6]. Sector-Specific Updates - **Innovative Drugs**: The index for innovative drugs rose by 0.34% last week, with a positive long-term outlook driven by clinical data and business development catalysts [6]. - **Generic Drugs**: The index increased by 1.69%, outperforming the pharmaceutical index. Key events include the approval of a compound release tablet by Shenda and the acceptance of a conditional listing application for a hemophilia drug [6]. - **Traditional Chinese Medicine & Pharmacies**: The Chinese medicine index rose by 0.39%, while pharmacies increased by 1.67%, with a focus on policy impacts and operational strategies [6]. - **Medical Devices**: The medical device index rose by 1.11%, with attention on equipment updates and market recovery [6]. - **Life Sciences**: The life sciences sector saw an average increase of 1.47%, with a focus on operational recovery and investment trends [6]. Additional Considerations - **Stock Selection**: Emphasis on companies with clean shareholding structures, low stock prices, and positive future operational trends. Monitoring monthly operational data and overall consumption data is crucial [7].

二、本次实施的权益分派方案 证券代码：002755 证券简称：奥赛康 公告编号：2025-036 北京奥赛康药业股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 北京奥赛康药业股份有限公司（以下简称"公司"）2024 年年度权益分派方案 已获 2025 年 5 月 29 日召开的 2024 年年度股东大会审议通过。现将权益分派事 宜公告如下： 一、股东大会审议通过权益分派方案情况 1、2025 年 5 月 29 日，北京奥赛康药业股份有限公司（以下简称"公司"） 2024 年年度股东大会审议通过了《关于公司 2024 年度利润分配预案的议案》， 同意以公司总股本 928,160,351 股为基数，向全体股东按每 10 股派发现金红利人 民币 1.20 元（含税），共计派发现金红利总额 111,379,242.12 元（含税），不进行 资本公积金转增股本，不送红股。自利润分配预案公布后至实施利润分配方案的 股权登记日期间，如公司总股本由于可转债转股、股份回购、股权激励行权、再 融资新增股份上市等原因发生变动，按照"现 ...

Core Viewpoint - The second batch of Yangtze River Delta Innovation Alliances has been officially announced, with three enterprises from Anhui leading the initiatives [1][4]. Group 1: Innovation Alliances - A total of 12 innovation alliances have been established, each led by a different company, focusing on various technological advancements [3]. - The leading companies and their respective innovation alliance names include: - Jiangsu Hengtong Optic-Electric Co., Ltd. leading the "Yangtze River Delta Marine Information Transmission Technology Innovation Alliance" - Jiangsu Aosaikang Pharmaceutical Co., Ltd. leading the "Yangtze River Delta Antimicrobial Infection Drug Research Innovation Alliance" - Nanjing Meichen Microelectronics Co., Ltd. leading the "Yangtze River Delta Low Earth Orbit Satellite Communication Integration Technology Innovation Alliance" - China Electronics Jinxin Digital Technology Group Co., Ltd. leading the "Yangtze River Delta Artificial Intelligence Source Network Collaborative Energy Management Innovation Alliance" - Shanghai Chemical Industry Research Institute Co., Ltd. leading the "Yangtze River Delta Isotope Technology Innovation Alliance" - Shanghai Yudu Semiconductor Technology Co., Ltd. leading the "Yangtze River Delta Electrical Measurement Equipment Innovation Alliance" - Zhejiang Jingsheng Mechanical and Electrical Co., Ltd. leading the "Yangtze River Delta Integrated Circuit Large Silicon Wafer Polishing Technology Innovation Alliance" - Hangzhou Shenhao Technology Co., Ltd. leading the "Yangtze River Delta Intelligent Robot Innovation Alliance" - Ningbo Geely Luoyou Engine Parts Co., Ltd. leading the "Yangtze River Delta Green Intelligent Powertrain Innovation Alliance" - Efort Intelligent Robot Co., Ltd. leading the "Yangtze River Delta Robot High-Speed High-Precision Technology Innovation Alliance" - Anhui Wanyi Technology Co., Ltd. leading the "Yangtze River Delta Wireless Minimally Invasive Surgery System Innovation Alliance" - Anhui Jianghuai Automobile Group Co., Ltd. leading the "Yangtze River Delta Automotive Low Carbon and Intelligent Technology Innovation Alliance" [3]. Group 2: Strategic Focus - The 12 innovation alliances are designed to address national strategic needs and align with local dominant industry directions, aiming to build an industrial chain around innovation [4]. - The goal is to promote the aggregation of various innovative elements towards the innovation alliances [4].

Investment Rating - The report maintains a "Positive" investment rating for the healthcare industry [10] Core Insights - Recent strategies in cancer immunotherapy focus on selectively delivering cytokines to tumor sites to extend their half-life and reduce systemic toxicity. This has led to the development of antibody-cytokine fusion proteins known as "immunocytokines," with significant potential in drug development. The most notable immunocytokines currently under development are IL-2, IL-12, and IL-15, with several domestic companies actively pursuing these therapies [2][6][24] Summary by Sections Immunocytokines and Their Development - Cytokine-based cancer immunotherapy aims to activate immune cells and enhance anti-tumor responses by modulating internal immune signaling. Commonly used cytokines include IL-2, IL-15, IL-12, and IFN-α, which can activate T cells and NK cells to improve tumor cell recognition and elimination [6][17] - The report highlights the emergence of a new strategy that selectively delivers cytokines to tumor sites, which has garnered clinical interest. This approach aims to enhance therapeutic efficacy while minimizing side effects [6][24] Domestic Company Developments - Several domestic pharmaceutical companies, including Innovent Biologics, Ascentage Pharma, and Junshi Biosciences, are making significant strides in the development of immunocytokine therapies. For instance, Innovent's IBI363, a novel PD-1/IL-2α-bias fusion protein, has shown promising clinical results in melanoma, colorectal cancer, and non-small cell lung cancer [7][44][48] - The report notes that IBI363 has demonstrated an overall response rate (ORR) of 26.4% in melanoma patients who previously failed immunotherapy, indicating its potential in treating resistant tumors [48] Market Outlook and Investment Opportunities - The macroeconomic environment has shifted, and by 2025, the report anticipates significant opportunities in the pharmaceutical sector driven by innovation and domestic demand recovery. Key investment themes include the international expansion of innovative drugs and the recovery of domestic healthcare services [8][67] - The report emphasizes the importance of selecting companies with strong cash flows, innovative capabilities, and established research platforms, particularly in the context of breakthrough therapies and technological advancements in the industry [67]